文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

支气管镜快速现场评估对重型侵袭性支气管肺曲霉病的诊断效能

[Diagnostic yield of bronchoscopic rapid on-site evaluation in severe invasive bronchopulmonary aspergillosis].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2023-01-01
一句话结论在微生物证据前,B-ROSE可辅助决定重型IBPA早期抗曲霉治疗,诊断符合率84.09%、ROC曲线下面积0.844。

该前瞻性队列研究纳入2014年6月至2022年6月新疆医科大学第一附属医院呼吸重症监护病房收治的176例疑似IBPA的重型肺炎患者,以国际侵袭性曲霉病定义为金标准,评估床旁支气管镜快速现场评估(B-ROSE)的诊断效能。B-ROSE诊断符合率84.09%(148/176),ROC曲线下面积0.844(95%CI 0.782-0.905),敏感度87.65%、特异度81.05%、阳性预测值79.78%、阴性预测值88.51%,漏诊率12.35%(10/81)、误诊率18.95%(18/95)。漏诊组长期(≥14天)使用糖皮质激素比例[70.0%(7/10)vs. 9.1%(7/77),P<0.01]和糖尿病比例[40.0%(4/10)vs. 10.4%(8/77),P<0.05]均高于真阴性组;误诊组长期使用糖皮质激素比例低于真阳性组[33.3%(6/18)vs. 60.6%(43/71),P<0.05],且B-ROSE显示黏膜白斑、黑斑及假膜的比例低于真阳性组[16.7%(3/18)vs. 52.1%(37/71),P<0.01]。作者认为,在获得微生物学证据前,B-ROSE可辅助重型IBPA早期抗曲霉治疗决策,方法快捷、简便、准确可靠。

要点

  • 疑似重型IBPA患者入RICU后24小时内尽快行床旁B-ROSE,以国际侵袭性曲霉病定义为金标准,诊断符合率84.09%(148/176)。
  • B-ROSE诊断重型IBPA的ROC曲线下面积0.844(95%CI 0.782-0.905),敏感度87.65%、特异度81.05%、阳性预测值79.78%、阴性预测值88.51%。
  • B-ROSE漏诊率12.35%(10/81)、误诊率18.95%(18/95);漏诊组长期(≥14天)使用糖皮质激素比例70.0%(7/10)vs. 真阴性组9.1%(7/77),P<0.01。
  • 漏诊组糖尿病比例40.0%(4/10)vs. 真阴性组10.4%(8/77),P<0.05;两组B-ROSE均见黏膜出血、充血水肿[100.0%(10/10)vs. 94.8%(73/77),P>0.05],提示急性黏膜炎症无特征性。
  • 误诊组B-ROSE黏膜白斑、黑斑及假膜比例16.7%(3/18)vs. 真阳性组52.1%(37/71),P<0.01;易误诊为IBPA的疾病为肺结核38.9%(7/18)、炎性肺腺癌27.8%(5/18)、肺血管炎16.7%(3/18)。

适用人群与场景

  • 2014年6月至2022年6月新疆医科大学第一附属医院呼吸重症监护病房(RICU)收治的疑似IBPA的重型肺炎患者。
  • 排除入院时主要以其他病原体(如细菌、结核分枝杆菌)感染的患者。

诊断标准与关键阈值

  • 以现行国际侵袭性曲霉病定义作为金诊断标准。
  • B-ROSE在入RICU后24小时内尽快实施,依据床旁B-ROSE结果决定是否启动抗真菌治疗。

处置流程与药物剂量

  • 入RICU后24小时内尽快行床旁支气管镜快速现场评估(B-ROSE),依据结果辅助决定是否启动早期抗曲霉治疗。

红旗征与不能漏的情况

  • B-ROSE缺乏特征性表现时,尤其对长期使用糖皮质激素或合并糖尿病的重型肺炎患者,需警惕IBPA漏诊。
  • 需警惕将肺结核、炎性肺腺癌、肺血管炎误诊为IBPA。

研究设计与关键结果

  • 前瞻性队列研究纳入176例疑似IBPA重型肺炎患者,按国际诊断标准IBPA 81例、非IBPA 95例;按B-ROSE早期诊断IBPA 89例、非IBPA 87例。
  • B-ROSE诊断符合率84.09%(148/176),诊断重型IBPA的ROC曲线下面积0.844(95%CI 0.782-0.905),敏感度87.65%、特异度81.05%、阳性预测值79.78%、阴性预测值88.51%。
  • B-ROSE漏诊率12.35%(10/81),误诊率18.95%(18/95)。
  • 与真阴性组比较,漏诊组长期(≥14天)使用糖皮质激素比例[70.0%(7/10)vs. 9.1%(7/77),P<0.01]和糖尿病比例[40.0%(4/10)vs. 10.4%(8/77),P<0.05]显著升高。
  • 漏诊组与真阴性组B-ROSE均显示黏膜出血、充血水肿[100.0%(10/10)vs. 94.8%(73/77),P>0.05],提示急性黏膜炎症无特征性。
  • 与真阳性组比较,误诊组长期(≥14天)使用糖皮质激素比例显著降低[33.3%(6/18)vs. 60.6%(43/71),P<0.05]。
  • 误诊组B-ROSE显示黏膜白斑、黑斑及假膜的比例显著低于真阳性组[16.7%(3/18)vs. 52.1%(37/71),P<0.01],提示长期使用糖皮质激素及B-ROSE见黏膜白斑、黑斑、假膜者误诊可能性较小。
  • 易误诊为IBPA的主要疾病:肺结核38.9%(7/18)、炎性肺腺癌27.8%(5/18)、肺血管炎16.7%(3/18)。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在获得微生物学证据前,B-ROSE可辅助重型IBPA早期抗曲霉治疗决策,该方法快捷、简便、准确可靠。
  • 作者认为,B-ROSE缺乏特征性表现时,尤其对长期使用糖皮质激素或糖尿病的重型肺炎患者,应注意IBPA漏诊。
  • 作者认为,对肺结核、炎性肺腺癌、肺血管炎等疾病应警惕误诊为IBPA。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To explore the diagnostic yield of bronchoscopic rapid on-site evaluation (B-ROSE) in patients with severe invasive bronchopulmonary aspergillosis (IBPA) and provide evidence for starting antifungal treatment before microbiological results were available.

METHODS: A prospective cohort study was conducted to select patients with severe pneumonia suspected of IBPA admitted to the respiratory intensive care unit (RICU) in the First Affiliated Hospital of Xinjiang Medical University from June 2014 to June 2022, and those who were primarily infected with other pathogens (such as bacteria, Mycobacterium tuberculosis) at admission were excluded. Whether the antifungal treatment was initiated or not on the basis of the bedside B-ROSE, the B-ROSE was administered as soon as possible within 24 hours after admission to RICU. The current international definition of invasive aspergillosis was used as the gold diagnostic standard, the diagnostic accordance rate, the sensitivity and specificity of B-ROSE were calculated respectively, and the receiver operator characteristic curve (ROC curve) was also plotted, to evaluate the predictive value in diagnosing IBPA.

RESULTS: A total of 176 patients with severe pneumonia suspected of IBPA were included in the study. According to international diagnostic standards, there were 81 cases of IBPA and 95 cases of non-IBPA. According to the early diagnosis of B-ROSE, there were 89 cases of IBPA and 87 cases of non-IBPA. The diagnostic accordance rate of B-ROSE was 84.09% (148/176), the area under the ROC curve for B-ROSE in diagnosing severe IBPA was 0.844, the 95% confidence interval (95%CI) was 0.782-0.905, the sensitivity was 87.65%, the specificity was 81.05%, the positive predictive value was 79.78%, the negative predictive value was 88.51%, the rate of underdiagnosis was 12.35% (10/81), and the rate of misdiagnosis was 18.95% (18/95). Compared with the true negative group, the proportion of long-term (≥ 14 days) use of glucocorticoid [70.0% (7/10) vs. 9.1% (7/77), P < 0.01] and the proportion of cases with diabetes [40.0% (4/10) vs. 10.4% (8/77), P < 0.05] were significantly higher in the false negative group (underdiagnosis group). However, B-ROSE of both groups showed mucosal bleeding, congestion and edema [100.0% (10/10) vs. 94.8% (73/77), P > 0.05], indicating that acute mucosal inflammation was non-characteristic. Compared with the true positive group, the proportion of long-term (≥ 14 days) use of glucocorticoid in the false positive group (misdiagnosis group) was significantly reduced [33.3% (6/18) vs. 60.6% (43/71), P < 0.05]. The B-ROSE results showed the proportion of cases with mucosal white spots, black plaques and pseudomembrane was significantly reduced [16.7% (3/18) vs. 52.1% (37/71), P < 0.01] in the misdiagnosed group, which suggest that cases of long-term use of glucocorticoid and cases with B-ROSE showing mucosal white spots, black plaques and pseudomembrane were less likely to be misdiagnosed. The main diseases that were easily misdiagnosed as IBPA included pulmonary tuberculosis (38.9%, 7/18), inflammatory lung adenocarcinoma (27.8%, 5/18) and pulmonary vasculitis (16.7%, 3/18).

CONCLUSIONS: Before obtaining microbiological evidence, B-ROSE can assist in decision-making of early anti-aspergillus treatment for severe IBPA. This method is prompt, simple, and has high accuracy and reliability. If B-ROSE lacks characteristic manifestations, especially for severe pneumonia in patients with long-term use of glucocorticoid or diabetes, attention should be paid to the underdiagnosis of IBPA. Diseases such as lung tuberculosis, inflammatory lung adenocarcinoma and lung vasculitis should be vigilant against misdiagnosis as IBPA.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Xu S, Wan Q, Li J, et al. [Diagnostic yield of bronchoscopic rapid on-site evaluation in severe invasive bronchopulmonary aspergillosis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023. PMID: 37987126. doi:10.3760/cma.j.cn121430-20230324-00214

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。